Envisia Therapeutics Selected To Present During Drug Delivery Company Showcase At 2015 Ophthalmalogy Innovation Summit

Company to Highlight Novel Approach to Developing Extended-Release Ocular Therapeutics

Nov 05, 2015, 08:20 ET from Envisia Therapeutics

RESEARCH TRIANGLE PARK, N.C., Nov. 5, 2015 /PRNewswire/ -- Envisia Therapeutics today announced that it has been selected to present during the Drug Delivery Company Showcase at the 2015 Ophthalmology Innovation Summit (OIS) being held at 8:30am PDT on November 12, 2015 at the Planet Hollywood Hotel in Las Vegas, Nevada.  Commonly referred to as OIS@AAO, the summit is held each year in conjunction with the American Academy of Ophthalmology (AAO) Annual Meeting to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.

"We are honored that Envisia has been selected to take part in the first ever OIS@AAO showcase for companies with differentiated drug delivery technologies," said Ben Yerxa, PhD, President of Envisia. "We have made a number of meaningful advancements in our pipeline this year through the development of several extended-release ocular therapies and we value the opportunity to highlight them."

Dr. Yerxa will present an overview of how Envisia is using the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology platform to create a wide array of novel small and large molecule delivery systems for the eye. 

The Company recently announced that it had achieved its primary efficacy endpoint in a phase 2a study investigating Envisia's lead product, ENV515, in patients with glaucoma.  ENV515 is a fully biodegradable PRINT particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than 6 months from a single dose.  ENV515 has the potential to address the issue of poor patient compliance that exists today with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss.  Envisia is also leveraging the Company's unique platform technology to develop products for other leading ocular diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation.

Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the Company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation.  Envisia is located in Research Triangle Park, North Carolina.  For more information, please go to www.envisiatherapeutics.com.

Logo - http://photos.prnewswire.com/prnh/20151006/274300LOGO

SOURCE Envisia Therapeutics